Biomarkers to identify IFN-beta drug response in Multiple Sclerosis

Developed by: Instituto de Investigación Sanitaria del Hospital Ramón y Cajal (IRYCIS)


Multiple sclerosis (MS) is an inflammatory disease in which the myelin of nerve cells in the brain and spinal cord are damaged. This damage disrupts the ability of parts of the nervous system to communicate, resulting in a wide range of signs and symptoms, including physical, mental, and sometimes psychiatric problems.

Currently there are many options for MS treatment, however is impossible to predict how each patient will respond to them

A priority in MS is to identify biomarkers that predict freedom from disease activity with a specific treatment.

The present invention refers to a method of predicting response of a human subject to Interferon beta (IFN-β), using as an indicator to classify responders the percentage of % CD5+Bcells and CD8+CD45+ perforin+ T cells before treatment in a biological sample from the patient.

Protected by Spanish patent application 2014 P201431314,  and PCT/EP2015/066163 in 2015.


Diego Velasco, Innovation Head


Emma González, Innovation Manager, PhD


Phone numbers: +34 91336 9132 / 9133

Comercializado, Transferible
Health technology:
Biotecnología y Diagnóstico Molecular (proteómica, genómica, etc...)